REGN logo

Regeneron Pharmaceuticals Inc. (REGN)

$902.90

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on REGN

Market cap

$93.40B

EPS

45.21

P/E ratio

18.4

Price to sales

4.95

Dividend yield

0.416%

Beta

0.098446

Price on REGN

Previous close

$930.67

Today's open

$938.51

Day's range

$901.53 - $948.11

52 week range

$591.52 - $991.73

Profile about REGN

CEO

Leonard S. Schleifer

Employees

15410

Headquarters

Tarrytown, NY

Exchange

Nasdaq Global Select

Shares outstanding

103447859

Issue type

Common Stock

REGN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on REGN

Why Regeneron (REGN) Might be Well Poised for a Surge

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

news source

Zacks Investment Research • Nov 4, 2026

news preview

REGN vs. ILMN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

news source

Zacks Investment Research • Nov 4, 2026

news preview

UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked Cleveland-Cliffs Inc. (NYSE:CLF).

news source

Benzinga • Nov 3, 2026

news preview

These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results. Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst consensus estimate of $16.19.

news source

Benzinga • Nov 2, 2026

news preview

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

news source

Benzinga • Nov 2, 2026

news preview

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter

As of Nov. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

news source

Benzinga • Nov 2, 2026

news preview

Regeneron: 3 Key Takeaways for Long-Term Investors

Dupixent global quarterly net sales grew 35% year over year to $6.5 billion. Total revenue increased 36% year over year to $5.1 billion.

news source

The Motley Fool • Oct 31, 2026

news preview

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call

Regeneron Pharmaceuticals NASDAQ: REGN reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT, EYLEA HD and LIBTAYO.

news source

MarketBeat • Oct 30, 2026

news preview

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Regeneron Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Regeneron Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in REGN on M1